Dr. Reddy’s Laboratories Ltd today announced the launch of lcosapent Ethyl Capsules, 1 gram approved by the U.S and Drug Administration (USFDA).
Dr. Reddy’s lcosapent Ethyl Capsules, 1 gram is approved for the following indication: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
ALSO READ: Aster DM Healthcare ties-up with Dr. Reddy’s Laboratories on Sputnik V Vaccine
It may be noted that Dr. Reddy’s lcosapent Ethyl Capsules is not approved for the following indication: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 500 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.
The effect of lcosapent Ethyl Capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has been determined, it said.
Dr. Reddy’s lcosapent Ethyl is available in 1 gram capsules in a bottle count size of 120’s count.
SOURCE-NSS
